Market Research Reports
Resources
About
Cart (0)

Oncology Adjuvants: Technologies and Global Markets

Report Code: PHM067A

Publish Date: Aug 2010

Publisher: BCC Publishing

Category: Pharmaceuticals

Customize This Report

Single User License: $2500

Member Price: FREE

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

  • The global human oncology adjuvants market was valued at $45.1 billion in 2009. This market is expected to reach $53 billion in 2010 and $91.7 billion in 2015, a compound annual growth rate (CAGR) of 11.6%
  • Breast cancer represents 28.9% of oncology adjuvant sales. This segment was worth $13 billion in 2009 and $13.7 billion in 2010 and will increase at a 9% compound annual growth rate (CAGR) to reach a value of nearly $21 billion in 2015.
  • The fastest area of sales growth overall is in the colorectal cancer space with a 16.1% compound annual growth rate (CAGR) forecast from the period of 2010 to 2015. This segment was worth $5.2 billion in 2009 and is expected to reach $8.7 billion in 2010 and $18.3 billion in 2015.

INTRODUCTION

STUDY GOALS AND OBJECTIVES

BCC’s goal in conducting this study was to determine the current status of the global oncolytic adjuvant marketplace and assess its growth potential over the five-year period from 2010 to 2015. We were particularly interested in approved oncology adjuvants and those that are late phase in the development pipeline. We have limited the scope of this report to the 30 Food and Drug Administration (FDA)- approved oncology adjuvants with antitumor or tissue protective activity. These therapies include the following product types: pharmaceuticals, immunotherapy, and radiosensitizing/radioprotective adjuvants.
 
Our key objective with this report is to produce an intensive analysis of the current oncology adjuvant marketplace in prostate, breast, and lung cancers, and to explore its future direction. In addition, we have included a detailed current review of other cancer indications, including colorectal, leukemias, lymphomas, digestive, urinary/reproductive systems, cutaneous, and other organ-based cancers.
 
We have specifically excluded a detailed analysis of medical devices; adjuvants to surgery; and other nonradiopharmaceutical, nonbiologic, nonnatural/herbal, nonpharmaceutical, nonbiologic therapies, though on occasion there may be limited discussion of significant developments. There is a limited discussion of preventive and therapeutic vaccines, which are FDA-approved in preneoplastic conditions such as human papillomavirus (HPV).
 
REASONS FOR DOING THIS STUDY
 
Cancerous and malignant tumors, particularly those that are in an advanced state, often are incurable and recurrent. Their etiologies are based on a host of factors ranging from genetics, radiation exposure, exposure to a chemical and/or biological carcinogen, and lifestyle factors, or any combination of the above. To further complicate treatment, there are issues of drug resistance, proper early diagnosis, and reoccurrence of the disease, while keeping the host healthy during treament.   As such, BCC was particularly interested in examining the oncology market of adjunctive therapies administered with traditional oncology treatments, which are the cutting edge of development in oncolytics.
 
INTENDED AUDIENCE
 
This report was prepared as a study of the global oncolytic adjuvant marketplace based on data of incidence and morality of selected cancer indications with a focus on human therapeutics. Information is presented on the oncology industry in general, including a focus on the adjuvants market segment including chemotherapies, immunotherapies, radiotherapeutics, and natural therapeutics that may enhance a medicinal or radiation therapy of a form of cancer; new technologies; new and novel drug applications; market-related issues; and in many cases actual revenue as displayed for the period of 2007 to 2009, with projections of trends and compound annual growth rates (CAGRs) through 2015.
 
This study will be of significant interest to hospitals, pharmacies, pharmaceutical companies, biopharmaceutical researchers, pharmaceutical company marketing executives, contract research organizations (CROs), chemists, physicians, nurses, physician assistants, pharmaceutical directors, product managers and representatives, and all manner of institutional directors ranging from nursing homes and schools, to those in long-term-care situations, both public and private. It will also be of interest to investment bankers in the biotechnology and pharmaceutical sectors, insurance executives, and oncology product marketing managers.
 
SCOPE OF REPORT
 
This study examines the human applications both marketed and in development of adjuvant technologies in oncology. In extensive analysis, BCC analyzes each market segment, presents its current market status and presents various forecasts for growth over the next 5 years. Other factors, such as FDA restrictions, government legislation, a cancer’s drug resistance to therapeutics, and/or natural and alternative remedies are also highlighted. Our financial and sales analysis focuses on the available figures from 2007 to 2009, with estimates for the years 2010 to 2015, including CAGR as a percentage.
 
METHODOLOGY
 
Both primary and secondary research methodologies were used in preparing this report. Through an extensive industry survey, inclusive of online database searches of industry-specific data sources, coupled with financial, trade, government, and marketing database sources, as well as interviews via correspondence or telephone with independent sources comprising companies, government agencies, and academic experts, BCC was able to compile data to present our analysis of the oncology adjuvant market, by market segment.
 
INFORMATION SOURCES
 
Of the companies and agencies surveyed, the majority were pharmaceutical or compound manufacturers. Additional information was supplied by known industry or trade sources.
 
ANALYST CREDENTIALS
 
Michael Delander is a biotechnology research consultant with more than 15 years of research experience. Michael has been consulting with venture capital-based start-ups and larger industry players since 2003, and has focused on in-depth research in a wide range of medical therapeutics in early development. His key published work is located in national and international organizations, including the National Library of Medicine, numerous Ivy League libraries, and the University of California.
 
BCC ONLINE SERVICES
 
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
  • Examine BCC’s complete catalog of Market Research Reports and place direct orders
  • Subscribe to any of BCC’s many industry newsletters
  • Read announcements of recently published reports and newly launched newsletters
  • Register for BCC’s well-known conferences
  • Request additional information on any BCC product
  • Take advantage of special offers
DISCLAIMER
 
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW
Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
[+] Show Chapter Details
Title/Chapter NamePagesMember Price
Full Report: Oncology Adjuvants: Technologies and Global Markets126Free
Chapter- 1: INTRODUCTION4Free
Chapter- 2: SUMMARY3Free
Chapter- 3: OVERVIEW10Free
Chapter- 4: TYPE OF APPLICATIONS IN THE HUMAN ONCOLOGY ADJUVANT MARKETPLACE: CHEMOTHERAPY, IMMUNOTHERAPY,AND RADIOTHERAPY 2Free
Chapter- 5: HUMAN CANCERS20Free
Chapter- 6: HUMAN ONCOLOGY ADJUVANTS14Free
Chapter- 7: TRADITIONAL MEDICINES7Free
Chapter- 8: GOVERNMENT REGULATORY AGENCIES AND PROFESSIONAL ASSOCIATIONS 6Free
Chapter- 9: MAJOR ONCOLOGY ADJUVANTS MANUFACTURERS19Free
Chapter- 10: ONCOLOGY ADJUVANTS INDUSTRY6Free
Chapter- 11: PATENT ANALYSIS30Free
Chapter- 12: APPENDIX5Free

Related Reports

Recent Reports

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Active Pharmaceutical Ingredients: Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM200C

The global market for active pharmaceutical ingredients (APIs) is estimated to increase from $247.8 billion in 2023 to reach $347.9 billion by 2029, at a compound annual growth rate (CAGR) of 5.9% from 2024 through 2029.

Global Market for Contract Research Organization (CRO) Services

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM186C

The global market for contract research organization (CRO) services is expected to grow from $111.8 billion in 2024 and is projected to reach $166.0 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.

Global Oncology Pharmaceuticals Market

Published - Oct 2024 | Publisher - BCC Publishing | Code - PHM256B

The global market for oncology pharmaceuticals is estimated to increase from $196.4 billion in 2023 to reach $401.4 billion by 2029, at a compound annual growth rate (CAGR) of 12.7% from 2024 through 2029.

Excipients in Pharmaceuticals: Global Markets to 2029

Published - Sep 2024 | Publisher - Gundreddy Gopinadh | Code - PHM010M

The global market for pharmaceutical excipients was valued at $9.2 billion in 2023. It is expected to grow from $9.7 billion in 2024 to $12.4 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2029.

Top Trending Reports

AI in Clinical and Molecular Diagnostics Market

Published - Oct 2024 | Publisher - BCC Publishing | Code - BIO261A

The global market for AI in clinical and molecular diagnostics is expected to grow from $2.6 billion in 2024 and is projected to reach $8.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.6% during the forecast period of 2024 to 2029.

Point-of-Care Diagnostics: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC043H

The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.

Medical Devices: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC170F

The global market for medical devices reached $739.6 billion in 2023. It is expected to grow from $810.4 billion in 2024 to $1.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

Global Artificial Intelligence (AI) Market: Investments vs Potential

Published - Aug 2024 | Publisher - BCC Publishing | Code - IFT189C

The global market for artificial intelligence (AI) is estimated to increase from $148.8 billion in 2023 to reach $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 39.7% from 2024 through 2029.

CRISPR Technology: Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC258C

The global market for CRISPR technology was valued at $3.4 billion in 2023. This market is expected to grow from $3.8 billion in 2024 to $7.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Oncology Adjuvants: Technologies and Global Markets
Customize This Report
Customize Report
Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.
Contact
© 2024 BCC Research
Privacy Policy |Site Map|Terms & Conditions